FORA Capital’s Spero Therapeutics SPRO Stock Holding History

FORA Capital’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,907	Closed	-$95K	–	1073
2020 Q4	$95K	Buy	+4,907	New	+$76.5K	0.01%	681

Other funds holding SPRO

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

FORA Capital's SPRO Position: Q1 2021 in Review

FORA Capital sold out of Spero Therapeutics (SPRO) in Q1 2021, closing a stake of 4,907 shares — an estimated $95K sold.

FORA Capital first reported a position in SPRO in Q4 2020 and held it in 1 quarter. The position peaked at $95K in Q4 2020. 94 funds tracked by Wall St. Rank hold SPRO as of Q1 2021.

FORA Capital reported no remaining Spero Therapeutics position as of Q1 2021 after selling out during the quarter.
FORA Capital sold 4,907 Spero Therapeutics shares in Q1 2021, an estimated $95K.
FORA Capital first reported a position in Spero Therapeutics in Q4 2020 and held it in 1 quarter.
FORA Capital's Spero Therapeutics position peaked at $95K in Q4 2020.
94 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2021.

Based on FORA Capital's 13F filing for Q1 2021, filed 17 May 2021.